← Back to Search

Proteasome inhibitor

panobinostat capsules for Multiple Myeloma (PANORAMA_3 Trial)

Phase 2
Waitlist Available
Research Sponsored by pharmaand GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
requiring treatment for relapsed or relapsed/refractory disease
1 to 4 prior lines of therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 30 and 70 months
Awards & highlights

PANORAMA_3 Trial Summary

This trial is investigating the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex to find the optimal regimen of PAN.

Eligible Conditions
  • Multiple Myeloma

PANORAMA_3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You need treatment because your disease has come back or is not responding to previous treatment.
Select...
You have received one to four previous treatment regimens.
Select...
You have taken IMiD medication before.

PANORAMA_3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 30 and 70 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 30 and 70 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response rate (ORR) up to 8 cycles
Secondary outcome measures
Duration of response (DOR)
European Organization of Research and Treatment of Cancer Quality of Life core 30-item questionnaire scores over time compared
Functional Assessment of Cancer Therapy / Gynecologic Oncology Group - Neurotoxicity scale scores over time
+13 more

PANORAMA_3 Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm C - 10mg PAN TIWExperimental Treatment3 Interventions
10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
Group II: Arm B - 20mg PAN BIWExperimental Treatment3 Interventions
20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
Group III: Arm A - 20mg PAN TIWExperimental Treatment3 Interventions
20mg panobinostat three times a week, 2 weeks on/1 week of in combination with s.c. bortezomib and p.o. dexamethasone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panobinostat
FDA approved
Bortezomib
FDA approved
Dexamethasone
FDA approved

Find a Location

Who is running the clinical trial?

pharmaand GmbHLead Sponsor
21 Previous Clinical Trials
3,926 Total Patients Enrolled
1 Trials studying Multiple Myeloma
248 Patients Enrolled for Multiple Myeloma
ppharmaand GmbHLead Sponsor
11 Previous Clinical Trials
1,515 Total Patients Enrolled
1 Trials studying Multiple Myeloma
248 Patients Enrolled for Multiple Myeloma
zr Pharma & GmbHLead Sponsor
20 Previous Clinical Trials
3,843 Total Patients Enrolled
1 Trials studying Multiple Myeloma
248 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned bortezomib injection?

"Given its status as a Phase 2 trial, with some evidence of safety but no data supporting efficacy, bortezomib injection received an overall score of 2."

Answered by AI

How many venues are administering this experiment?

"At this time, 11 trial locations are actively enrolling patients. These sites span from Kitchener to Atlanta and Edmonton with other convenient spots throughout the country. To reduce travel needs while partaking in the study, make sure you select a nearby centre."

Answered by AI

What other explorations have been done with bortezomib injection?

"Bortezomib injection was first tested in 2002 at Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, and has since been the subject of 1435 completed medical trials. At present, 603 clinical trials are actively recruiting patients; a significant proportion of these studies taking place in Kitchener, Ontario."

Answered by AI

For what conditions is bortezomib injection typically prescribed?

"Bortezomib injections have the capacity to treat ophthalmic, sympathetic, and eye-related conditions such as branch retinal vein occlusion."

Answered by AI

Is enrollment for this experiment open at present?

"Unfortunately, this research effort is not enrolling patients at present. Although first posted on April 27th 2016 and recently updated on March 15th 2021, it has yet to resume recruitment of subjects. However, there are presently 807 clinical trials searching for individuals with multiple myeloma and 603 recruiting those in need of bortezomib injections."

Answered by AI

How many participants is this medical experiment currently treating?

"Recruitment for this trial has ended. Initially posted on April 27th, 2016 and last updated March 15th 2021; if you are looking for an alternative research opportunity there are presently 807 multiple myeloma studies and 603 bortezomib injection trials accepting applicants."

Answered by AI
~28 spots leftby Mar 2025